Clinical trial · Interventional
Prayer as a Possible Adjuvant Treatment for Breast Cancer
Prayer as a Possible Adjuvant Treatment for Breast Cancer - A Randomized Partially Blinded Controlled Clinical Trial Evaluating the Effect of Prayer on Humoral and Biochemical Parameters in Stage I-IV Breast Cancer
NCT00519545CI-TRIAL-00006121completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this study is to help determine the biochemical mechanisms underlying previously demonstrated health benefits of prayer, and to track humoral changes in various prayer activities.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Prayer | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 1
- description
- scripted prayer group (intervention group)
- interventionNames
- Behavioral: Prayer
- type
- NO_INTERVENTION
- label
- 2
- description
- no prayer intervention group (non-intervention group)
Primary outcomes (3)
- measure
- A. Evaluate the effect of prayer on humoral (including biochemical/physiological inflammatory/immune) parameters approximately every three months at the subjects routine oncology visit.
- timeFrame
- 2 years
- measure
- B. Monitor changes in cancer- related biomarkers, and evaluate these changes in relation to the participants' prayer activities as recorded since the previous oncology visit.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 21 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Primary histological diagnosis of Stage I-IV breast cancer. 2. Initial diagnosis of breast cancer within 5 year of study enrollment. 3. Not currently receiving chemotherapy or radiation therapy. Hormone therapy is allowed. 4. Life expectancy of at least 12 months. 5. ECOG performance status of 0, 1, or 2. 6. Willing to sign informed consent indicating that they are aware of the investigational nature of the study and the randomized study design. 7. Willing to comply with monthly follow-up phone calls. 8. Willing to complete questionnaires at regular oncology clinic visits. 9. Able to read write \& understand English. Exclusion Criteria: 1. Concurrent treatment with chemotherapy or radiation therapy 2. Less than 3 months since last dose of chemotherapy or radiation therapy. 3. Breast cancer diagnosis more than 5 years prior to study enrollment 4. Less than 21 or greater than to 80 years old. 5. Life threatening or severe concurrent non-malignant conditions. 6. Uncontrolled diabetes mellitus. 7. Severe heart disease. 8. Severe liver disease. Severe lung disease. 9. History of smoking within 5 years of study enrollment. 10. Psychological or psychiatric disorder that would interfere with study compliance. 11. History of missed appointments or poor medical compliance. 12. Inability to understand instructions on how to complete a questionnaire. 13. No access to a phone.
References
Publications (0)
Data not yet available
No reference posted for this study.